Compare ADMA Biologics Inc (ADMA) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Yum! Brands, Inc. — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Yum! Brands, Inc. trades at $144.74 (market cap $39.50B). The key difference: Yum! Brands, Inc. is far larger — about 17.8× ADMA Biologics Inc's market cap, and Yum! Brands, Inc. pays a 2.07% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | YUM | |
|---|---|---|
Market Cap | $2.22B | $39.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $168.16 |
52-Week Low | $7.60 | $138.21 |
Enterprise Value | $2.29B | $51.10B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.
Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.
YUM trades at $150.15, up 3.32% in the past 24 hours, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings show a Q2 2026 beat with EPS of $1.62 versus $1.57 expected, while revenue grew to $8.21B in 2025. The company completed the sale of Pizza Hut China for $1.2B in August 2026, aiming to streamline operations and reduce debt. Cash flow from operations improved to $2.01B in 2025, supporting a dividend payment of $0.75 per share.
The outlook is mixed, with analyst consensus leaning hold (56.87%) but a price target of $174.60 implying 16% upside. Risks include ongoing legal investigations and a parasite outbreak impacting Taco Bell sales, though management reports recovery. Debt remains high at $11.25B long-term, but the debt-to-asset ratio improved to 143.49 in 2025. Execution on digital growth and brand focus post-Pizza Hut sale are key to unlocking value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
